Backchannelmedia

Business Wire

Joint Venture Partner Projects First Full Year's U.S. Gross Revenues to Exceed $100 Million

eFoodSafety.com Inc. (OTCBB: EFSF) and CK41 Direct Inc. jointly announced today the signing of a joint venture agreement. CK41 Direct Inc. is a firm engaged in the marketing, production and distribution of infomercials. The board of directors of CK41 boasts several infomercial successes, such as "Ab Away Pro," "Body by Jake" fitness products and "Rapid White" tooth whitening system. Other successes include the "Ab Sculptor" with more than $100 million in sales and the "Ab Doer" with sales in excess of $350 million.

The agreement calls for CK41 to handle and fund all aspects of the production, distribution and marketing of the anti-acne product, whose leading competition in the marketplace had sales in excess of $300 million last year.

eFoodSafety.com Inc. will soon announce the branded and trademarked name of the product, as well as its high-profile celebrity spokesperson. Within the next 60 days, CK41 will commence the scripting and production of the infomercial.

"CK41 anticipates estimated revenue at more than $100 million in gross sales in the first full year of the infomercial's national roll-out in the U.S. market alone," stated Christine McDonald, president and CEO of CK41 Direct. McDonald further stated, "Worldwide appeal for the product could easily approach $200 million as the leading competitor's sales have already exceeded $300 million last year."

"We are elated to report this significant event to our shareholders. We have aligned ourselves with a joint venture partner who is well-capitalized, knowledgeable, focused on the product's target market, and has a seasoned staff and board of directors who have been an integral part of some of the most successful direct response campaigns ever launched," stated Patricia Gruden, president and CEO of eFoodSafety.com.

About eFoodSafety.com Inc.

eFoodSafety.com Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus -- EPA Reg. No. 82723-1, that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, and Avian Influenza and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.